Anticancer effect of metformin and regulation on HIF-1α

Abstract

Abstract: Studies show that metformin inhibits the proliferation of several types of cancer cells. All evidences, therefore propose the antitumor effect of metformin. Metformin can repress the oxygen consumption of tumor cells, and suppress hypoxiainducible factor-1α (HIF-1α) accumulation through the translational and posttranslational mechanisms, and suppress the expression of HIF-1α by activating AMPactivated protein kinase (AMPK).

Key words: Metformin, Neoplasms, Hypoxiainducible factor 1, alpha subunit

GAO Jun-Rong, ZHANG Ti, CAO Man-Qing, ZHANG Xue-Jun, ZHU Xiao-Lin. Anticancer effect of metformin and regulation on HIF-1α[J]. Journal of International Oncology, 2016, 43(2): 113-.

References

［1］ Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?［J］. Oncologist, 2004, 9Suppl 5: 3140. DOI:10.1634/theoncologist.99000531. ［2］ Ben Sahra I, Le MarchandBrustel Y, Tanti JF. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?［J］. Mol Cancer Ther, 2010, 9(5): 10921099. DOI: 10.1158/15357163.MCT091186. ［3］ Bonini MG, Gantner BN. The multifaceted activities of AMPK in tumor progressionwhy the "one size fits all" definition does not fit at all?［J］. IUBMB Life, 2013, 65(11): 889896. DOI:10.1002/iub.1213. ［4］ Shi WY, Xiao D, Wang L, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy［J］. Cell Death Dis, 2012, 3(3): e275. DOI:10.1038/cddis.2012.13. ［5］ Saito T, Chiba T, Yuki K, et al. Metformin, a diabetes drug, eliminates tumorinitiating hepatocellular carcinoma cells［J］. PLoS One, 2013, 8(7): e70010. DOI:10.1371/journal.pone.0070010. ［6］ Song CW, Lee H, Dings RP, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells［J］. Sci Rep, 2012, 2: 362. DOI:10.1038/srep00362. ［7］ Queiroz EA, Puukila S, Eichler R, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF7 breast cancer cells［J］. PLoS One, 2014, 9(5): e98207. DOI:10.1371/journal.pone.0098207. ［8］ Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1AMPK pathway regulates p27(kip1)phosphorylation mediating the decision to enter autophagy or apoptosis［J］. Nat Cell Biol, 2007, 9(2): 218224. ［9］ Short JD, Houston KD, Dere R, et al. AMPactivated protein kinase signaling results in cytoplasmic sequestration of p27［J］. Cancer Res, 2008, 68(16): 64966506. DOI:10.1158/00085472.CAN075756. ［10］ Samani AA, Yakar S, Leroith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights［J］. Endocr Rev, 2007, 28(1): 2047. DOI:10.1210/er.20060001. ［11］ Scotlandi K, Picci P. Targeting insulinlike growth factor 1 receptor in sarcomas［J］. Curr Opin Oncol, 2008, 20(4): 419427. DOI:10.1097/CCO.0b013e328302edab. ［12］ Garofalo C, Capristo M, Manara MC, et al. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug［J］. PLoS One, 2013, 8(12): e83832. DOI:10.1371/journal.pone.0083832. ［13］ Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning［J］. Cancer Discov, 2012, 2(9): 778790. DOI:10.1158/21598290.CD120263. ［14］ Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapyinduced AMPK activation and antitumoral growth［J］. Clin Cancer Res, 2011, 17(12): 39934005. DOI:10.1158/10780432.CCR102243. ［15］ Zannella VE, Dal Pra A, Muaddi H, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response［J］. Clin Cancer Res, 2013, 19(24): 67416750. DOI:10.1158/10780432.CCR131787. ［16］ Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission［J］. Cancer Res, 2009, 69(19): 75077511. DOI:10.1158/00085472.CAN092994. ［17］ Blandino G, Valerio M, Cioce M, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and cMYC［J］. Nat Commun, 2012, 3: 865. DOI:10.1038/ncomms1859. ［18］ Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF1α expression and Oxygen metabolism［J］. Diabetes, 2011, 60(3): 981992. DOI:10.2337/db100655. ［19］ Ece H, Cigdem E, Yuksel K, et al. Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif1 alpha and 8Ohdg levels?［J］. Asian Pac J Cancer Prev, 2012, 13(10): 51435148. ［20］ Krymskaya VP, Snow J, Cesarone G, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia［J］. FASEB J, 2011, 25(6): 19221933. DOI:10.1096/fj.10175018. ［21］ Ranasinghe WK, Sengupta S, Williams S, et al. The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer［J］. Cancer Med, 2014, 3(2): 245251. DOI:10.1002/cam4.189. ［22］ Ling S, Feng T, Ke Q, et al. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines［J］. Oncol Rep, 2014, 31(6): 26112618. DOI:10.3892/or.2014.3151. ［23］ Sheng B, Liu J, Li GH. Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling［J］. Comp Biochem Physiol B Biochem Mol Biol, 2012, 163(1): 5158. DOI:10.1016/j.cbpb.2012.04.009.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.